Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

PROXERA PSOMED 20 - normalizing cream, 20% urea
Diagnosis of plaque psoriasis (not palmoplantar) for at least 1 year PROXERA PSOMED 40 - intensive exfoliating gel, 40% urea
Diagnosis of non-pustular palmoplantar psoriasis for at least 1 year
Age 18-65 years
"Mild" psoriasis severity according to:
Psoriasis Area Severity Index (PASI) \<10
Dermatologic Life Quality Index (DLQI) \<10
Body Surface Area (BSA) \<10

Product intolerance
Concomitant therapy with systemic immunomodulatory drugs (e.g., methotrexate, cyclosporine, apremilast)
Concomitant therapy with biologic drugs such as anti-TNFα, anti-IL17, or anti-IL23.
Concomitant topical therapy with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations.
Pregnant or breastfeeding women

Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis